Delivery strategies for antiparasitics

Bibliography

• SHU YZ: Recent natural products based drug development: a pharmaceutical industry perspective. j Nat. Rev (1998) 61:1053–1071.
   Google Scholar
• ALLSOP E: New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. Curi: Opin. (1998) 1:530–534.
   PubMed Web of Science ®Google Scholar
• O'RIORDAN T, FARIS M: Inhaled antimicrobial therapy. Respir. Care Clin. N Am. (1999) 5:617–631.
   PubMedGoogle Scholar
• RIZZARDI GP LAZZARIN A, MUSICCO M et al.: Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Prieumacystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. j Infect. (1995) 31:99–105.
   Google Scholar
• KREUTER J: Nanoparticles and microparticles for drug and vaccine delivery. Anat. (1996) 189:503–505.
   PubMed Web of Science ®Google Scholar
• BARRATT GM: Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today (2000) 3:163–171.
   PubMedGoogle Scholar
• LEE VHL, YANG JJ: Oral drug delivery. In: Drug Delivery and Targeting. A Hillery, A Lloyd, J Swarbrick (Eds), Taylor & Francis, London (2000:269–300.
   Google Scholar
• FASANO A: Innovative strategies for the oral delivery of drugs and peptides. Trends Biatechnol. (1998) 16:152–157.
   PubMed Web of Science ®Google Scholar
• VERMA RK, KRISHNA DM, GARG S: Formulation aspects in the development of osmotically controlled oral drug delivery systems. j Control Release (2002) 79:7–27.
   PubMed Web of Science ®Google Scholar
• LAMBKIN I, PINILLA C: Targeting approaches to oral drug delivery. Expert Opin. Biol. Ther (2002) 2:67–73.
   PubMed Web of Science ®Google Scholar
• KAYSER 0: A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int. j Pharm. (2001) 214:83–85.
   PubMed Web of Science ®Google Scholar
• MOLLER RH, JACOBS C, KAYSER 0: Nanosuspensions for the formulation of poorly soluble drugs. In: Pharmaceutical Emulsions and Suspensions. F Nielloud, G Marti-Mestres (Eds), Marcel Dekker, New York/Basel (2000:409–464.
   Google Scholar
• ROBERTS MS, WALTERS K: The relationship between structure and barrier function of skin. In: Dermal Absorption and Toxicity Assessment. MS Roberts, K Walters (Eds), Marcel Dekker, New York/Basel (1998):1–42.
   Google Scholar
• HADGRAFT J, PUGH WJ: The selection and design of topical and transdermal agents: a review. I Invest. Dermatal. Symp. Proc. (1998) 3:131–135.
   PubMedGoogle Scholar
• GAMIER T, CROFT SL: Topical treatment for cutaneous leishmaniasis. Curr. Opin. Invest. Drugs (2002) 3:538–544.
   PubMedGoogle Scholar
• ••First comprehensive review comparingtopical formulations for cutaneous leishmaniasis in a systematic manner.
   Google Scholar
• ABDI YA, GUSTAFSON LL, ERICSSON 0, HELLGREN U: Handbook of drugs for Tropical Parasitic Infections. Taylor & Francis, Oxford, London (1995).
   Google Scholar
• EL-ON J, LIVSHIN R, EVEN-PAZ Z, HAMBURGER D, WEINRAUCH L: Topical treatment of cutaneous leishmaniasis. j Invest. Dermatal. (1986) 87:284–288.
   PubMed Web of Science ®Google Scholar
• SOTO J, FUYA P, HERRERA R, BERMAN J: Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis. (1998) 26:56–58.
   PubMed Web of Science ®Google Scholar
• NEAL RA, MURPHY AG, OLLIARO P, CROFT SL: Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis. Trans. R. Soc. Trap. Med. Hyg. (1994) 88:223–225.
   Web of Science ®Google Scholar
• BEN SALAH A, ZAKRAOUI H, ZAATOUR A et al: A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. j Trap. Med. Hyg. (1995) 53:162–166.
   Web of Science ®Google Scholar
• ASILIAN A, JALAYER T, WHITWORTH JA, GHASEMI RL, NILFOROOSHZADEH M, OLLIARO P: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am. j Trap. Med. Hyg. (1995) 53:648–651.
   Web of Science ®Google Scholar
• SOTO JM, TOLEDO JT, GUTIERREZ P et al.: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase II pilot study. Am. Trap. Med. Hyg. (2002) 66:147–151.
   PubMed Web of Science ®Google Scholar
• ZVULUNOV A, KLAUS S, VARDY D: Fluconazole for the treatment of cutaneous leishmaniasis. N Engl. j Med. (2002) 347:370–371.
   PubMed Web of Science ®Google Scholar
• BRAJTBURG J, BOLARD J: Carrier effects on biological activity of amphotericin B. Chit. Microbial Rev. (1996) 9:512–531.
   Google Scholar
• ••A comprehensive overview on clinicallyused AmB formulations.
   Google Scholar
• SCHMIDT-OTT R, KLENNER T, OVERATH P, ABISCHER T: Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R. Soc. Trap. Med. Hyg. (1999) 93:85–90.
   Web of Science ®Google Scholar
• TAYLOR G, KELLAWAY I: Pulmonary drug delivery. In: Drug Delivery and Targeting. A Hillery, A Lloyd, J Swarbrick (Eds), Taylor & Francis, London (2000:269–300.
   Google Scholar
• ••First textbook summarising interdisciplinary work on drug delivery in a single book.
   Google Scholar
• NIVEN RW: Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12:151–231.
   PubMed Web of Science ®Google Scholar
• ••Covering major biopharmaceutical aspectsand presenting technical details on inhalers.
   Google Scholar
• SIMONDS AK, NEWMAN SP, JOHNSON MA, TALAEE N, LEE CA, CLARKE SW: Alveolar targeting of aerosol pentamidine. Toward a rational delivery system. Am. Rev Respir. Dis. (1990) 141:827–829.
   PubMedGoogle Scholar
• GUDE JK: Selective delivery of pentamidine to the lung by aerosol. Am. Rev Respir Dis. (1989) 139:1060.
   PubMed Web of Science ®Google Scholar
• KREUTER J: Colloidal Drug Delivery Systems. Marcel Dekker, Inc., New York (1994).
   Google Scholar
• BETAGERI, GURU V, JENKINS, SCOTT A, PARSONS, DANIEL L: Liposome Drug Delivery Systems. Technomic Publishing Company, Lancaster, Pennsylvania, USA (1993).
   Google Scholar
• MAURIN M, RAOULT D: Optimum treatment of intracellular infections. Drugs (1996) 52:45–59.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM AC: Parasitic adaptive mechanisms in infection by Leishmania. Exp. Mol. Pathol. (2002) 72:132–141.
   PubMed Web of Science ®Google Scholar
• BERMAN JD, EDWARDS N, KING M, GROGL M: Biochemistry of pentostam resistant Leishmania. Am. J. Trop. Med. Hyg. (1989) 40:159–164.
   PubMed Web of Science ®Google Scholar
• KREUTER J: Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. (1994) 19:253–256.
   PubMed Web of Science ®Google Scholar
• MOLLER RH, JACOBS C, KAYSER 0: Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deify. Rev (2001) 47:3–19.
   PubMed Web of Science ®Google Scholar
• PILENI, MP, TANORI, J, FILANKEMBO A: Biomimetic strategies for the control of size, shape and self-organization of nanoparticles. Colloid Surfaces A: Physicochem. Engineer. Aspects (1996) 123–124:561–573.
   Google Scholar
• DOUGLAS SJ, DAVIS SS, ILLUM L: Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1987) 3:233–261.
   PubMed Web of Science ®Google Scholar
• KREUTER J: Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deify. Rev. (2001) 47:65–81.
   PubMed Web of Science ®Google Scholar
• KREUTER J, SHAMENKOV D, PETROV V et al.: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. I Drug Target. (2002) 10:317–325.
   PubMed Web of Science ®Google Scholar
• GESSNER A, OLBRICH C, SCHRODER W, KAYSER 0, MOLLER RI-I: The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. (2001) 214:87–91.
   PubMed Web of Science ®Google Scholar
• PAUL M, DURAND R, BOULARD Y et al Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. I Drug Target. (1998) 5:481–490.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-MARTIN G, MERINO I, RODRIGUEZ-CABEZAS MN, TORRES M, NUNEZ R, OSUNA A: Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. Pharm. Pharmacol. (1998) 50:29–35.
   PubMed Web of Science ®Google Scholar
• AHSAN E RIVAS II KHAN MA, TORRES SUAREZ Al: Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. I Control Release. (2002) 79:29–40.
   PubMed Web of Science ®Google Scholar
• SZOKA F Jr, PAPAHADJOPOULOS D:Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev Biophys. Bioeng. (1980) 9:467–508.
   PubMedGoogle Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27:603–618.
   PubMed Web of Science ®Google Scholar
• COUVREUR E FATTAL E, ANDREMONT A: Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm. Res. (1991) 8:1079–1086.
   PubMed Web of Science ®Google Scholar
• COUNE A: Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience. Infection (1988) 16:141–147.
   Google Scholar
• ALVING CR, STECK EA, CHAPMAN WL Jr, WAITS VB, HENDRICKS LD, SWARTZ GM Jr, HANSON WL: Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Nati Acad. Sd. USA (1978) 75:2959–2963.
   PubMed Web of Science ®Google Scholar
• CROFT SL, YARDLEY V: Chemotherapy of leishmaniasis. Curr. Pharm. Des. (2002) 8:319–342.
   PubMed Web of Science ®Google Scholar
• MEDDA S, MUKHOPADHYAY S, BASU MK: Evaluation of the in vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal form. J. Antimicrob. Chemother. (1999) 44:791–794.
   PubMed Web of Science ®Google Scholar
• DUFFELS A, GREEN LG, LEY SV, MILLER AD: Synthesis of high-mannose type neoglycolipids: active targeting of liposomes to macrophages in gene therapy. Chemistry (2000) 14:1416–1430.
   Google Scholar
• NAN A, NANAYAKKARA NP, WALKER LA, YARDLEY V, CROFT SL, GHANEHARI H: N-(2-hydroxapropyOmethacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J. Control. Release (2001) 77:233–243.
   PubMed Web of Science ®Google Scholar
• PAPAHADJOPOULOS D, VAIL WJ, JACOBSON K, POSTE G: Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta (1975) 394:483–491.
   PubMed Web of Science ®Google Scholar
• WALKER SA, KENNEDY MT, ZASADZINSKI JA: Encapsulation of bilayer vesicles by self-assembly. Nature (1997) 387:61–64.
   PubMed Web of Science ®Google Scholar
• SANTANGELO R, PADERU P, DELMAS G et al.: Efficacy of oral cochleate- amphotericin B in a mouse model of systemic candidiasis. Antimicrob. Agents Chemother. (2000) 44:2356–2360.
   PubMed Web of Science ®Google Scholar
• MARTI-MESTRES G, NIELLOUD F: Main surfactants used in the pharmaceutical field. In: Pharmaceutical Emulsions and Suspensions. F Nielloud, G Marti-Mestres (Eds), Marcel Dekker, New York/Basel (2000):1–18.
   Google Scholar
• BUSZELLO K, MOLLER BW: Emulsions as drug delivery systems. In: Pharmaceutical Emulsions and Suspensions. F Nielloud, G Marti-Mestres (Eds), Marcel Dekker, New York/Basel (2000):191–228.
   Google Scholar
• GANGNEUX JP, SULAHIAN A, GARIN YJ, FARINOTTI R, DEROUIN F: Therapy of visceral leishmaniasis due to Leishmania infaritum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. (1996) 40:1214–1218.
   PubMed Web of Science ®Google Scholar
• CHAVANET P: Amphotericin B deoxycholate (Fungizone): old drug, new versions. Rev Med. Interne (1997) 18:153–165.
   PubMed Web of Science ®Google Scholar
• CARTER KC, MULLEN AB, SUNDAR S, KENNEY RT: Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. (2001) 45:3555–3559.
   PubMed Web of Science ®Google Scholar
• WASHINGTON C, LANCE M, DAVIS SS: Toxicity of amphotericin B emulsion formulations. J. Antimicrob. Chemother. (1993) 31:806–808.
   PubMed Web of Science ®Google Scholar
• Polymeric Drugs And Drug Delivery Systems. RL Dunn, RM Ottenbrite (Eds), American Chemical Society, Washington DC, USA (1991).
   Google Scholar
• SMITH A, HUNNEYBALL IM: Evaluation of poly(lactic acid) as biodegradable drug delivery system for parenteral administration. Int. J. Pharm. (1986) 36:215–220.
   Google Scholar
• BAILLIE AJ, COOMBS GH, DOLAN TF et al.: Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. j Pharm. Pharmacol. (1987) 39:832–835.
   PubMed Web of Science ®Google Scholar
• VENIER-JULIENNE MC, BENOIT JP: Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm. Acta Helv. (1996) 71:121–128.
   PubMedGoogle Scholar
• MANDAL TK: Effect of solvent on the characteristics of pentamidine loaded microcapsule. I Biomater. Sci. Polym. Ed. (1999) 10:1–17.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-MARTIN G, FIGUEROA C, MERINO I, OSUNA A: Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur. I Pharm. Biopharm. (2000) 49:137–142.
   PubMed Web of Science ®Google Scholar
• LEES RE: Trial of an enteric-coated preparation of lucanthone hydrochloride in Schistosoma martsorti infection. Tins. R. Soc. Trop. Med. Hyg. (1967) 61:806–811.
   PubMed Web of Science ®Google Scholar
• KATZ N, PELLEGRINO J, OLIVEIRA CA: Further clinical trials with hycanthone, a new antischistosomal agent. Am. j Trop. Med. Hyg. (1969) 18:924–929.
   PubMed Web of Science ®Google Scholar
• ZHU DY, FU S, WU WL, QIAN YD, FENG MY, WANG MJ: Comparative study of two kinds of enteric-coated furapromidum with rectal dipterex in treatment for schistosomiasis. Zhorigguo Yi Xue Ke Xue Yuan Xue Bao (1980) 2:277–278.
   PubMedGoogle Scholar
• MARITZ JC: Hycanthone therapy in bilharziasis. S. Air Med. j (1970) 44:126–128
   PubMedGoogle Scholar
• RINGWALD P, BICKII J, SAME-EKOBO A, BASCO LK: Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob. Agents Chemother. (1997) 41:2317–2319.
   PubMed Web of Science ®Google Scholar
• HUANG ZS, FENG Z, MENG F et al: Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients. ZhongguoJi Sheng Chong Xue Yu fi Shrug Chong Bing Za Zhi (1989) 7:19–21.
   PubMedGoogle Scholar
• GHOSAL S, KRISHNAPRASAD BN, KHANNA M et al: 3'-deoxyribonucleosides and their derivatives as anti-amoebic agents. Int. Pharm. (2000) 194:15–20.
   PubMed Web of Science ®Google Scholar
• SCHENONE H, VILLARROEL F, SCHENONE L, GALDAMES M, ROMERO E, JIMENEZ M: Treatment of infections by Entamoeba histolytica and Ciardia lamblia with different dosages of 100 mg tinidazole enteric coated tablets. Bo/. Chil. Parasitol (1979) 34:2–6.
   PubMedGoogle Scholar
• BUCKTON G: Interfacial Phenomena in Drug Delivery and Targeting. Harwood Academic Publishers (1995).
   Google Scholar
• BOLARD J, ANDREMONT A: Lipid formulations of amphotericin B: from clinical trials to in vitro studies. In: Liposomes, New Systems and New Trends in their Application. F Puisieux, P Couvreur, J Delattre, JP Devissaguet (Eds), Editions de Sante, Paris (1995):397–428.
   Google Scholar
• GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A, CREMOPHOR EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. j Cancer (2001) 37:1590–1598.
   PubMed Web of Science ®Google Scholar
• ALBERS E, MOLLER BW: Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12:311–337.
   PubMed Web of Science ®Google Scholar
• WONG JW, YUEN KH: Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins. mt. j Pharm. (2001) 227:177–185.
   Google Scholar
• MULLEN AB, CARTER KC, BAILLIE AJ: Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother (1997) 41:2089–2092.
   PubMed Web of Science ®Google Scholar
• JUST-NUBLING G: Therapy of candidiasis and cryptococcosis in AIDS. Mycoses (1994) 37\(Suppl. 2):56–63.
   Google Scholar
• CASTRO-HERMIDA JA, GONZALEZ-LOSADA Y, FREIRE-SANTOS F, MEZO-MENENDEZ M, ARES-MAZAS E: Evaluation of beta-cyclodextrin against natural infections of cryptosporidiosis in calves. Vet. Parasitol (2001) 101:85–89.
   PubMed Web of Science ®Google Scholar
• McKELLAR QA: Chemotherapy and delivery systems - helminths. Vet. Parasitol (1994) 54:249–258.
   PubMed Web of Science ®Google Scholar
• ANDERSON N, LABY RH, PRICHARD RK, HENNESSY D: Controlled release of anthelmintic drugs: a new concept for prevention of helminthiasis in sheep. Res. Vet. Li. (1980) 29:333–341.
   PubMed Web of Science ®Google Scholar